Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial
Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected with HIV-1. Rilpivirine, a new non-nucleoside reverse transcriptase inhibitor, has shown similar antiviral efficacy to efavirenz in a phase 2b trial w...
محفوظ في:
المؤلفون الرئيسيون: | Molina J., Cahn P., Grinsztejn B., Lazzarin A., Mills A., Saag M., Supparatpinyo K., Walmsley S., Crauwels H., Rimsky L., Vanveggel S., Boven K. |
---|---|
التنسيق: | دورية |
منشور في: |
2017
|
الوصول للمادة أونلاين: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79960381844&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/43029 |
الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
المؤسسة: | Chiang Mai University |
مواد مشابهة
-
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial
بواسطة: Jean Michel Molina, وآخرون
منشور في: (2018) -
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials
بواسطة: Cohen C., وآخرون
منشور في: (2017) -
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials
بواسطة: Calvin J. Cohen, وآخرون
منشور في: (2018) -
Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO)
بواسطة: David A. Wohl, وآخرون
منشور في: (2018) -
Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine
بواسطة: David V. Glidden, وآخرون
منشور في: (2018)